EPHX2 and hypertensive disorder: These findings highlight an attractive direction to develop sEH inhibition as a novel therapeutic target for aging-related disease intervention, given that a series of sEH inhibitors are under clinical development for pain [41], hypertension [42], chronic obstructive pulmonary disease [43], and osteoarthritis [24].